08 December 2023: Clinical Research
Efficacy Analysis of Neoadjuvant versus Adjuvant Cisplatin-Paclitaxel Regimens for Initial Treatment of FIGO Stages IB3 and IIA2 Cervical Cancer
Wei Tao 1DEF* , Weiqi Wang 1CDF , Jingfang Zhai 2BCF , Linlin Guo 1ABFDOI: 10.12659/MSM.940545
Med Sci Monit 2023; 29:e940545
Table 1 Demographic and clinical characteristics of patients before chemoradiotherapies.
| Characteristics | Cohort | Comparisons | |||||
|---|---|---|---|---|---|---|---|
| NT | AT | ||||||
| Numbers of women | 105 | 140 | P value | df | Test value | 95% CI | |
| Age (years) | 41 (50-33) | 43 (50.5-39) | 0.1058 (Mann-Whitney test) | N/A | 6461.5 | N/A | |
| Hemoglobin (g/dL) | 10.02±0.06 | 10.16±0.04 | 0.0579 (Unpaired t test with Welch correction) | 203 | 1.907 | −0.004744 to 0.2862 | |
| Platelet (×10)/L | 341 (457-138) | 380 (428-231) | 0.8935 (Mann-Whitney test) | N/A | 7276 | N/A | |
| Body mass index (kg/m) | 24 (25.5-23) | 24 (25-23) | 0.7202 (Mann-Whitney test) | N/A | 7153 | N/A | |
| Tumor size (cm) | 5.6 (7.6-3.05) | 6 (7.15-3.05) | 0.7129 (Mann-Whitney test) | N/A | 7147.5 | N/A | |
| FIGO stage | IB3 | 60 (57) | 74 (53) | 0.5195 (χ test with Yate’s correction) | 1 | 0.2886 | 0.8235 to 1.481 |
| IIA2 | 45 (43) | 66 (47) | |||||
| FIGO – The International Federation of Gynecology and Obstetrics; IB3 – larger than 4 cm; IIA2 – spread from the cervix to the upper two-thirds of the vagina; df – degree of freedom; N/A – not applicable; CI – confidence interval (using the approximation of Katz for χ test). Parameters are depicted as frequencies (percentages) or mean ± standard error of the mean (SEM) or median (Q3-Q1). All results were considered significant if the value was less than 0.05. Test value (Mann-Whitney statistics for Mann-Whitney test, Welch’s approximate t value for unpaired test with Welch correction, χ value for χ test). | |||||||